Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

Publication Title

Cardiology clinics

Authors

Radica Alicic, Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.Follow
Joshua J Neumiller, Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USAFollow

Document Type

Article

Publication Date

8-1-2025

Keywords

Humans; Glucagon-Like Peptide-1 Receptor Agonists; Cardiovascular Diseases; Glucagon-Like Peptide 1; Gastric Inhibitory Polypeptide; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glucagon-Like Peptide-1 Receptor; Cardiovascular outcome trials; Dulaglutide; Exenatide; Incretin hormones; Liraglutide; Pathomechanisms; Semaglutide; Tirzepatide.; washington; spokane; pmrc

Abstract

Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our understanding of their beneficial effects on cardiovascular-kidney-metabolic conditions. Large clinical outcome trials have established GLP-1 receptor agonists as guideline-directed therapies to improve glycemia, achieve, and maintain weight management goals, and mitigate cardiovascular and kidney risk, with early evidence suggesting similar benefits with the dual GIP/GLP-1 receptor agonist tirzepatide.

Area of Special Interest

Cardiovascular (Heart)

Area of Special Interest

Kidney & Diabetes

Specialty/Research Institute

Cardiology

Specialty/Research Institute

Nephrology

Specialty/Research Institute

Endocrinology

DOI

10.1016/j.ccl.2024.12.003